Latest Close
$3.23
Stock Hub
ACHV
Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$0.81 (+33.47%)
Market Cap
$171,965,168.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$1.84 to $6.03
Target Mean Price
$14.75
Beta
1.96
Trailing P/E
Not available
Forward P/E
-3.11
Price / Book
8.00
Company Overview
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.